+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

U.S. Platelet Rich Plasma Market Size, Share & Trend Analysis By Type (Pure PRP, Leukocyte Rich PRP), By Application (Sports Medicine, Orthopedics, Dermatology, Cosmetic Surgery), By End-use, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 70 Pages
  • May 2023
  • Region: United States
  • Grand View Research
  • ID: 5165387
The U.S. platelet rich plasma market size is expected to reach USD 493.79 million by 2030, registering a CAGR of 10.5% over the forecast period. Platelet-rich plasma (PRP) has gained significant popularity in the field of orthopedics, neurosurgery, ophthalmology, and cosmetic surgery as it integrates modern technology with the body's capability to accelerate healing. A rise in the incidence of musculoskeletal disorders, orthopedic disorders, and sports injuries has encouraged clinicians to embrace minimally invasive platelet rich plasma therapy with less risk of therapy-associated adverse effects, which propels the market growth.

As per the International Osteoporosis Foundation, around 52.0 million people suffered from osteoporosis or low bone mass in 2010 and are expected to reach 61.0 million by 2020 in the U.S. Besides, platelet rich plasma injections have been highlighted in numerous medical journals as a promising technique to heal damaged tissues. The studies have reported improved function and lesser pain after receiving these therapies than traditional standard care, thus driving its adoption rate.

Platelet rich plasma-based therapies continue to evolve as a popular treatment in the dermatology field. It is increasingly being preferred for skin rejuvenation, hair restoration, dermal augmentation, acne scars, and striae distensae. Moreover, the combination of platelet rich plasma with laser therapies, dermal fillers, micro-needling, and autologous fat grafting generates synergistic effects that lead to optimized aesthetic outcomes. The confluence of these factors boosts the penetration of these therapies in dermatology applications.

The emergence of platelet rich plasma products for point-of-care settings is another factor fostering market progression. Several POC systems are available in the market place that is specifically engineered and validated to deliver fast POC treatments within a few minutes. HEALEON HD PRP from HEALEON MEDICAL, INC., is one such FDA-approved Class II medical device that is designed for autologous platelet rich plasma preparation at the patient’s POC settings.

U.S. Platelet Rich Plasma Market Report Highlights

  • The leukocyte-rich platelet rich plasma segment is expected to witness a significant increase in the commercial pool and number of experimental studies expanding its applications across orthopedic, general surgery, and sports medicine
  • Numerous advancements in leukocyte PRP market space by manufacturers, mainly in protocol automation to maximize the standardization of plasma preparations are driving the segment
  • The cosmetic surgery and dermatology application segment is expected to foresee the highest growth rate during the overcast period
  • This is due to a rapid increase in preference among the consumers as injections based on this therapy help to achieve fuller facial features without opting for commercial fillers
  • Platelet rich plasma systems are estimated to witness the fastest growth rate throughout the forecast period in the sports medicine application
  • The advent of novel separation systems by key manufacturers that are specific to platelet rich plasma applications as well as functions vertically and are applicable across autologous cellular therapies boost the growth of these systems
  • Numerous medical visits, high burden of orthopedic disorders particularly in geriatric population, and widespread application of this therapy for musculoskeletal injuries result in the dominant share of hospitals in 2019
  • More than 300,000 old aged people, over 65 years, are hospitalized for hip fractures every year in the U.S.
  • This high hospitalization rate surges the incorporation of platelet rich plasma as an adjunctive use in hip surgeries in hospital settings
  • Key manufacturers are implementing business strategies such as broadening of product portfolio, widening of distribution network, and collaborations and mergers to reinforce their significant share in the market.

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Definitions
1.1.1.1 Type Segment
1.1.1.2 Application Segment
1.1.1.3 End-USE Segment
1.2 Estimates and Forecast Timeline
1.3 Information Procurement
1.4 Objectives
1.4.1 Objective - 1
1.4.2 Objective - 2
1.4.3 Objective - 3
1.5 Research Methodology
1.6 Information Procurement
1.6.1 Purchased Database
1.6.2 GVR’s Internal Database
1.6.3 Secondary Sources
1.6.4 Primary Research
1.7 Information or Data Analysis
1.7.1 Data Analysis Models
1.8 Market Formulation & Validation
1.9 Model Details
1.9.1 Commodity Flow Analysis
1.10 List of Secondary Sources
1.11 List of Abbreviations
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Type, Application, and End Use Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
3.3.1 Increasing number of cosmetic surgery procedures
3.3.2 Rise in the incidence of orthopedic disorders and sports injuries
3.3.3 Extending medical applications of platelet rich plasma
3.5. Market Restraint Analysis
3.5.1. High costs associated with PRP products
3.6. Business Environment Analysis
3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.6.2. Porter’s Five Forces Analysis
3.6.3. COVID-19 Impact Analysis
Chapter 4. The U.S. Platelet Rich Plasma Market: Segment Analysis by Type, 2018 - 2030 (USD Million)
4.1. U.S. Platelet Rich Plasma Market: Type Movement Analysis
4.2. Pure PRP
4.2.1. The U.S. pure PRP market estimates and forecast, 2018 - 2030 (USD Million)
4.3. Leukocyte Rich PRP
4.3.1. The U.S. leukocyte rich PRP market estimates and forecast, 2018 - 2030 (USD Million)
4.4. Others
4.4.1. The U.S. other type market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 5. The U.S. Platelet Rich Plasma Market: Segment Analysis by Application, 2018 - 2030 (USD Million)
5.1. The U.S. Platelet Rich Plasma Market: Application Movement Analysis
5.2. Orthopedics
5.2.1. The U.S. platelet rich plasma for orthopedics market estimates and forecast, 2018 - 2030 (USD Million)
5.3. Sports Medicine
5.3.1. The U.S. platelet rich plasma for Sports Medicine market estimates and forecast, 2018 - 2030 (USD Million)
5.4. Cosmetic Surgery
5.4.1. The U.S. platelet rich plasma for cosmetic surgery market estimates and forecast, 2018 - 2030 (USD Million)
5.5. Dermatology
5.5.1. The U.S. platelet rich plasma for dermatology market estimates and forecast, 2018 - 2030 (USD Million)
5.5.2. The U.S. platelet rich plasma for ulcer healing dermatology market estimates and forecast, 2018 - 2030 (USD Million)
5.5.2.1. The U.S. platelet rich plasma for venous ulcer market estimates and forecast, 2018 - 2030 (USD Million)
5.5.2.2. The U.S. platelet rich plasma for traumatic ulcer market estimates and forecast, 2018 - 2030 (USD Million)
5.5.2.3. The U.S. platelet rich plasma for diabetic ulcer market estimates and forecast, 2018 - 2030 (USD Million)
5.5.2.4. The U.S. platelet rich plasma for pyoderma gangrenosum ulcer market estimates and forecast, 2018 - 2030 (USD Million)
5.5.2.5. The U.S. platelet rich plasma for trophic ulcer market estimates and forecast, 2018 - 2030 (USD Million)
5.5.2.6. The U.S. platelet rich plasma for vasculitic ulcer market estimates and forecast, 2018 - 2030 (USD Million)
5.5.2.7. The U.S. platelet rich plasma for other ulcer market estimates and forecast, 2018 - 2030 (USD Million)
5.5.3. The U.S. platelet rich plasma for other dermatology market estimates and forecast, 2018 - 2030 (USD Million)
5.6. Ophthalmic surgery
5.6.1. The U.S. platelet rich plasma for ophthalmic surgery market estimates and forecast, 2018 - 2030 (USD Million)
5.7. Neurosurgery
5.7.1. The U.S. platelet rich plasma for general surgery market estimates and forecast, 2018 - 2030 (USD Million)
5.8. General Surgery
5.8.1. The U.S. platelet rich plasma for general surgery market estimates and forecast, 2018 - 2030 (USD Million)
5.9. Others
5.9.1. The U.S. platelet rich plasma for others market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 6. The U.S. Platelet Rich Plasma Market: Segment Analysis by End Use, 2018 - 2030 (USD Million)
6.1. U.S. Platelet Rich Plasma Market: End Use Movement Analysis
6.2. Hospitals
6.2.1. The U.S. platelet rich plasma for hospitals market estimates and forecast, 2018 - 2030 (USD Million)
6.3. Clinics
6.3.1. The U.S. platelet rich plasma for clinics estimates and forecast, 2018 - 2030 (USD Million)
6.4. Others
6.4.1. The U.S. platelet rich plasma market for other end user estimates and forecast, 2018 - 2030 (USD Million)
Chapter 7. Company Profile
7.1. Company Categorization
7.2. Strategy Mapping
7.2.1. New Product Launch
7.2.2. Partnerships
7.2.3. Acquisition
7.2.4. Collaboration
7.2.5. Funding
7.3. Key Company Market Share Analysis, 2022
7.3.1. Company Profiles
7.3.2. Johnson & Johnson
7.3.2.1. Company overview
7.3.2.2. DePuy Synthes
7.3.2.2.1. Company overview
7.3.2.2.2. Financial Performance
7.3.2.2.3. Product benchmarking
7.3.2.2.4. Strategic initiatives
7.3.3. Arthrex, Inc.
7.3.3.1. Company overview
7.3.3.2. Financial Performance
7.3.3.3. Product benchmarking
7.3.3.4. Strategic initiatives
7.3.4. EmCyte Corporation
7.3.4.1. Company overview
7.3.4.2. Product benchmarking
7.3.4.3. Strategic initiatives
7.3.5. DR. PRP America, Llc
7.3.5.1. Company overview
7.3.5.2. Product benchmarking
7.3.6. Juventix
7.3.6.1. Company overview
7.3.6.2. Financial Performance
7.3.6.3. Product benchmarking
7.3.7. Terumo Corporation
7.3.7.1. Company overview
7.3.7.2. Terumo Bct, Inc.
7.3.7.2.1. Company overview
7.3.7.2.2. Financial Performance
7.3.7.2.3. Product benchmarking
7.3.7.2.4. Strategic initiatives
7.3.8. Zimmer Biomet
7.3.8.1. Company overview
7.3.8.2. Financial Performance
7.3.8.3. Product benchmarking
7.3.8.4. Strategic initiatives
7.3.9. Stryker
7.3.9.1. Company overview
7.3.9.2. Financial Performance
7.3.9.3. Product benchmarking
7.3.9.4. Strategic initiatives
7.3.10. Apex Biologix
7.3.10.1. Company overview
7.3.10.2. Financial Performance
7.3.10.3. Product benchmarking
7.3.10.4. Strategic initiatives
7.3.11. Celling Biosciences
7.3.11.1. Company overview
7.3.11.2. Financial Performance
7.3.11.3. Product benchmarking
7.3.11.4. Strategic initiatives
List of Tables
Table 1. List of abbreviation
Table 2. List of secondary sources
Table 3. The U.S. Platelet Rich Plasma (PRP) Market, By Type, 2018 - 2030 (USD Million)
Table 4. The U.S. Platelet Rich Plasma (PRP) Market, By Application, 2018 - 2030 (USD Million)
Table 5. The U.S. Platelet Rich Plasma (PRP) Market, By End-use, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 U.S. Platelet Rich Plasma (PRP) Market: Market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Value chain-based sizing & forecasting
Fig. 10 Platelet rich plasma (PRP) market snapshot, 2022 (USD Million)
Fig. 11 Market driver relevance analysis (Current & future impact)
Fig. 12 Prevalence rate of arthritis in the U.S. adults, diagnosed and projected cases
Fig. 13 Incidence of arthritis in U.S., by age
Fig. 14 Common minimal invasive procedures in 2021, U.S.
Fig. 15 Market restraint relevance analysis (Current & future impact)
Fig. 16 Market opportunity relevance analysis (Current & future impact)
Fig. 17 The U.S. Platelet rich plasma (PRP) market SWOT analysis
Fig. 18 The U.S. Platelet rich plasma (PRP) market Porter’s five forces analysis
Fig. 19 The U.S. Platelet rich plasma (PRP) market: Type outlook and key takeaways
Fig. 20 The U.S. Platelet rich plasma (PRP) market: Type movement analysis
Fig. 21 The U.S. Pure PRP market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 The U.S. Leukocyte rich PRP market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 The U.S. PRP market estimates and forecast for others, 2018 - 2030 (USD Million)
Fig. 24 The U.S. Platelet rich plasma (PRP) market: Application outlook and key takeaways
Fig. 25 The U.S. Platelet rich plasma (PRP) market: Application movement analysis
Fig. 26 The U.S. Platelet rich plasma (PRP) market estimates and forecast for orthopedics, 2018 - 2030 (USD Million)
Fig. 27 The U.S. Platelet rich plasma (PRP) market estimates and forecast for sports medicine, 2018 - 2030 (USD Million)
Fig. 28 The U.S. Platelet rich plasma (PRP) market estimates and forecast for cosmetic surgery, 2018 - 2030 (USD Million)
Fig. 29 The U.S. Platelet rich plasma (PRP) market estimates and forecast for dermatology, 2018 - 2030 (USD Million)
Fig. 30 The U.S. Platelet rich plasma (PRP) market estimates and forecast for ulcer healing, 2018 - 2030 (USD Million)
Fig. 31 The U.S. Platelet rich plasma (PRP) market estimates and forecast for venous ulcers, 2018 - 2030 (USD Million)
Fig. 32 The U.S. Platelet rich plasma (PRP) market estimates and forecast for traumatic ulcers, 2018 - 2030 (USD Million)
Fig. 33 The U.S. Platelet rich plasma (PRP) market estimates and forecast for pyoderma gangrenosum ulcers, 2018 - 2030 (USD Million)
Fig. 34 The U.S. Platelet rich plasma (PRP) market estimates and forecast for diabetic ulcers, 2018 - 2030
Fig. 35 The U.S. Platelet rich plasma (PRP) market estimates and forecast for trophic ulcers, 2018 - 2030
Fig. 36 The U.S. Platelet rich plasma (PRP) Market estimates and forecast for vasculitic ulcers, 2018 - 2030 (USD Million)
Fig. 37 The U.S. Platelet rich plasma (PRP) Market estimates and forecast for ulcer healing for others, 2018 - 2030 (USD Million)
Fig. 38 The U.S. Platelet rich plasma (PRP) Market estimates and forecast for other dermatology, 2018 - 2030 (USD Million)
Fig. 39 The U.S. Platelet rich plasma (PRP) market estimates and forecast for ophthalmic surgery, 2018 - 2030 (USD Million)
Fig. 40 The U.S. Platelet rich plasma (PRP) market estimates and forecast for neurosurgery, 2018 - 2030 (USD Million)
Fig. 41 The U.S. Platelet rich plasma (PRP) market estimates and forecast for general surgery, 2018 - 2030
Fig. 42 The U.S. Platelet rich plasma (PRP) market estimates and forecast for others, 2018 - 2030 (USD Million)
Fig. 43 The U.S. Platelet rich plasma (PRP) market: End-use outlook and key takeaways
Fig. 44 The U.S. Platelet rich plasma (PRP) market: End-use movement analysis
Fig. 45 The U.S. Platelet rich plasma (PRP) market for hospitals, 2018 - 2030 (USD Million)
Fig. 46 The U.S. Platelet rich plasma (PRP) market for clinics, 2018 - 2030 (USD Million)
Fig. 47 The U.S. Platelet rich plasma (PRP) market for others, 2018 - 2030 (USD Million)
Fig. 48 Strategy framework
Fig. 49 Market participation categorization

Companies Mentioned

  • Johnson & Johnson
  • Arthrex, Inc.
  • EmCyte Corporation
  • DR. PRP America, Llc
  • Juventix
  • Terumo Corporation
  • Zimmer Biomet
  • Stryker
  • Apex Biologix
  • Celling Biosciences

Methodology

Loading
LOADING...

Table Information